YHB Investment Advisors Inc. Sells 54 Shares of Becton, Dickinson and Company (NYSE:BDX)

YHB Investment Advisors Inc. cut its holdings in Becton, Dickinson and Company (NYSE:BDX) by 0.6% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 9,675 shares of the medical instruments supplier’s stock after selling 54 shares during the period. YHB Investment Advisors Inc.’s holdings in Becton, Dickinson and Company were worth $2,333,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in the business. Livelsberger Financial Advisory bought a new position in shares of Becton, Dickinson and Company in the 3rd quarter valued at about $26,000. Sound Income Strategies LLC lifted its stake in Becton, Dickinson and Company by 35.8% in the third quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock valued at $40,000 after acquiring an additional 44 shares during the last quarter. Opal Wealth Advisors LLC bought a new position in shares of Becton, Dickinson and Company in the 2nd quarter valued at about $45,000. Abound Wealth Management increased its stake in shares of Becton, Dickinson and Company by 96.0% during the 2nd quarter. Abound Wealth Management now owns 196 shares of the medical instruments supplier’s stock worth $46,000 after purchasing an additional 96 shares during the last quarter. Finally, Chilton Capital Management LLC increased its position in Becton, Dickinson and Company by 1,233.3% during the second quarter. Chilton Capital Management LLC now owns 200 shares of the medical instruments supplier’s stock worth $47,000 after buying an additional 185 shares during the last quarter. Institutional investors and hedge funds own 86.97% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on BDX. Stifel Nicolaus raised their price objective on Becton, Dickinson and Company from $270.00 to $280.00 and gave the company a “buy” rating in a research report on Friday, July 26th. Citigroup raised shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and increased their price target for the company from $255.00 to $275.00 in a report on Tuesday, October 1st. Evercore ISI boosted their price objective on Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. StockNews.com upgraded Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Thursday, August 8th. Finally, Raymond James decreased their price target on shares of Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating on the stock in a research note on Friday, August 2nd. Nine research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $282.63.

Becton, Dickinson and Company Trading Up 0.3 %

Shares of Becton, Dickinson and Company stock opened at $240.52 on Thursday. The company has a quick ratio of 1.36, a current ratio of 1.85 and a debt-to-equity ratio of 0.70. Becton, Dickinson and Company has a 12-month low of $218.75 and a 12-month high of $262.23. The company has a market capitalization of $69.51 billion, a price-to-earnings ratio of 52.98, a PEG ratio of 1.79 and a beta of 0.42. The firm’s 50-day moving average price is $237.33 and its two-hundred day moving average price is $235.16.

Becton, Dickinson and Company (NYSE:BDX) last released its earnings results on Thursday, August 1st. The medical instruments supplier reported $3.50 earnings per share for the quarter, topping the consensus estimate of $3.31 by $0.19. Becton, Dickinson and Company had a return on equity of 14.49% and a net margin of 7.13%. The firm had revenue of $4.99 billion during the quarter, compared to analysts’ expectations of $5.08 billion. During the same period in the prior year, the company earned $2.96 earnings per share. The company’s quarterly revenue was up 2.3% on a year-over-year basis. On average, analysts forecast that Becton, Dickinson and Company will post 13.11 earnings per share for the current fiscal year.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.